Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Abdulraheem Alshangiti"'
Autor:
Kholoud Alwosaibai, Salmah Aalmri, Miral Mashhour, Salim Ghandorah, Abdulraheem Alshangiti, Faisal Azam, Waleed Selwi, Lubna Gharaibeh, Yasser Alatawi, Zainab Alruwaii, Hashem O. Alsaab
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-16 (2023)
Abstract Background Immune checkpoint inhibitors, including PD-L1 (programmed death ligand-1) inhibitors have well documented anticancer therapeutic effect in most types of cancers but its use in the treatment of ovarian cancer is not yet proven. The
Externí odkaz:
https://doaj.org/article/1a9a4c43945e478886149e8da0565315
Autor:
Nedal Bukhari, Abdulraheem Alshangiti, Emad Tashkandi, Mohammed Algarni, Humaid O. Al-Shamsi, Hamoud Al-Khallaf
Publikováno v:
Clinics and Practice, Vol 11, Iss 3, Pp 467-471 (2021)
Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities to standard dose 5-FU based
Externí odkaz:
https://doaj.org/article/b59602066cf7468bbbe7ac0368d66f7c
Autor:
Humaid O. Al-Shamsi, Mohammed Algarni, Abdulraheem Alshangiti, Hamoud Al-Khallaf, Emad Tashkandi, Nedal Bukhari
Publikováno v:
Clinics and Practice, Vol 11, Iss 62, Pp 467-471 (2021)
Clinics and Practice
Volume 11
Issue 3
Pages 62-471
Clinics and Practice
Volume 11
Issue 3
Pages 62-471
Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities to standard dose 5-FU based
Autor:
Gang Wang, Alexander W. Wyatt, Fred Saad, Gillian Vandekerkhove, Elie Ritch, Sebastien J. Hotte, Steven Yip, Martin E. Gleave, Sinja Taavitsainen, Scott North, Cameron Herberts, Anna Gleave, Matti Annala, Ben Tran, Elena Schönlau, Kim N. Chi, Nayyer Iqbal, Andrew J. Murtha, Abdulraheem Alshangiti, Simon Yuen Fai Fu, Kevin Beja, Arkhjamil Angeles
Publikováno v:
Clinical Cancer Research. 26:A24-A24
Background: Hotspot activating mutations in AKT1 and PIK3CA represent a rare but potentially unique subset of metastatic prostate cancers (mPCa). The accompanying genomic and clinical features of these patients are currently unknown. Preclinical evid
Publikováno v:
The American journal of medicine. 128(2)